FDA Approves New Drug for Arthritis
Posted on: Wednesday, 28 December 2005, 15:00 CST
By The Associated Press
WASHINGTON - Bristol-Myers Squibb Co. said the FDA has approved a new drug to treat moderate to severe cases of rheumatoid arthritis, a chronic disease that afflicts more than 2 million Americans.
The drug, abatacept, will be marketed as Orencia and is designed to be given intravenously. The company, based in New York, intends to start selling it by the end of February.
The drug acts by suppressing part of the immune system to treat rheumatoid arthritis, which causes swelling, stiffness and pain in the linings of the joints. The linings become inflamed after the body's immune system acts against them.
Source: Record, The; Bergen County, N.J.
Related Articles
- The Drug Information Center Arthritis Project: Providing Patients With Interactive and Reliable Arthritis Internet Education
- WHO Programme for International Drug Monitoring
- Abnormal Drug Response: Opportunities for Risk Reduction Through Pharmacogenetics
- Advances in Single-Patient Trials for Drug Treatment Optimization and Risk Management*
- 12 Freed for Texas Drug Bust Appeals
- 12 Freed in Appeal of Texas Drug Busts
- 'Rapid Detox' Breaks Drug Habits Quickly
- Advisers: Arthritis Drug Not Too Risky
- 55 Charged With Selling Drug Gear Online
- ADHD Drug Prescriptions Vary by ZIP Code
Rating: 3.3 / 5 (6 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds